Equillium, Inc. (EQ) News
Filter EQ News Items
EQ News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EQ News Highlights
- For EQ, its 30 day story count is now at 2.
- Over the past 1 day, the trend for EQ's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest EQ News From Around the Web
Below are the latest news stories about EQUILLIUM INC that investors may wish to consider to help them evaluate EQ as an investment opportunity.
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development UpdatesLA JOLLA, Calif., March 23, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the fourth quarter and full year 2022 and provided corporate and clinical development updates. |
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease ConferenceLA JOLLA, Calif., March 22, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference. |
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTRLA JOLLA, Calif., February 17, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an oral presentation was given yesterday afternoon at the Tandem Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research. |
Equillium to Present at the SVB Securities Annual Global Healthcare ConferenceLA JOLLA, Calif., February 07, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the SVB Securities Annual Global Biopharma Conference. |
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRLA JOLLA, Calif., January 13, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research. The Hybrid meetings will take place virtually |
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger AgreementLA JOLLA, Calif., December 23, 2022--Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement. |
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative ColitisLA JOLLA, Calif., December 16, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited, in collaboration with Equillium, has initiated a Phase 2 clinical study of itolizumab in patients with ulcerative colitis (UC). |
Autoimmune Biotech Scores $26M Payment, Up To $139M To Advance Phase 3 ResearchEquillium Inc (NASDAQ: EQ) announced an option and asset purchase agreement through which Ono Pharmaceutical Co Ltd gains the exclusive option to purchase Equillium's rights to itolizumab. These rights include all therapeutic indications and the rights to commercialize itolizumab in the U.S., Canada, Australia, and New Zealand. Through this partnership, Equillium has secured the resources necessary to continue advancing the Phase 3 EQUATOR study of itolizumab in the treatment of first-line acute |
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of ItolizumabLA JOLLA, Calif., December 06, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. ("Ono"), today announced an option and asset purchase agreement through which Ono gains the exclusive option to purchase Equillium’s rights to itolizumab, a first-in-class monoclonal antibody targeting CD6. These rights include all therapeutic indications and the r |
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical UpdatesLA JOLLA, Calif., November 14, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the third quarter 2022 and provided an update on its clinical development programs. |